Targeting apoptosis proteins in hematological malignancies
- 28 May 2013
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 332 (2), 325-334
- https://doi.org/10.1016/j.canlet.2011.06.016
Abstract
No abstract availableKeywords
This publication has 106 references indexed in Scilit:
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaBritish Journal of Cancer, 2010
- XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AMLApoptosis, 2010
- Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expressionProceedings of the National Academy of Sciences of the United States of America, 2010
- Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycinLeukemia, 2010
- Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-α and TRAIL-initiated apoptotic signalsExperimental Hematology, 2008
- A Short Nur77-Derived Peptide Converts Bcl-2 from a Protector to a KillerCancer Cell, 2008
- Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProceedings of the National Academy of Sciences of the United States of America, 2007
- c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosisThe EMBO Journal, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticProceedings of the National Academy of Sciences of the United States of America, 2006